Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) EBT Margin (2016 - 2025)

Altimmune (ALT) has disclosed EBT Margin for 16 consecutive years, with 380280.0% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin rose 7662000.0% to 380280.0% in Q3 2025 year-over-year; TTM through Sep 2025 was 423570.0%, a 22445462.0% decrease, with the full-year FY2024 number at 475535.0%, down 45477279.0% from a year prior.
  • EBT Margin was 380280.0% for Q3 2025 at Altimmune, up from 442920.0% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 164.27% in Q4 2021 to a low of 1188150.0% in Q3 2022.
  • A 5-year average of 274407.62% and a median of 251650.0% in 2022 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: tumbled -116694114bps in 2022, then skyrocketed 118243978bps in 2023.
  • Altimmune's EBT Margin stood at 164.27% in 2021, then plummeted by -50613bps to 83307.69% in 2022, then dropped by -3bps to 85570.27% in 2023, then crashed by -445bps to 465960.0% in 2024, then increased by 18bps to 380280.0% in 2025.
  • Per Business Quant, the three most recent readings for ALT's EBT Margin are 380280.0% (Q3 2025), 442920.0% (Q2 2025), and 405120.0% (Q1 2025).